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Introduction 81 82
Sleep disruption is associated with obesity and type 2 diabetes (T2D), yet the 83 bidirectional relationship between sleep and glucose metabolism is not fully understood. It is 84 linked to increased diabetes prevalence in both experimental [1] [2] [3] [4] and epidemiological studies [5] [6] [7] . 85
In addition, the severity of hyperglycemia in individuals with diabetes is associated with poor 86 sleep quality 8,9, 10, 11 , short sleep duration 8, 9, 12, 13 and a greater tendency to develop sleep 87 disorders including obstructive sleep apnea (OSA) 14, 15 . Both the International Diabetes 88 Federation (IDF) and American Diabetes Association (ADA) recommend evaluating T2D 89 patients for sleep breathing problems especially OSA and strongly encourage treatment when 90 found 16, 17 . 91
Weight loss is one of the most effective ways to improve sleep quality, quantity 92 [Yannakoulia, 2017 and Xanthpoulos 2018] and to treat OSA in obese patients. Lifestyle 93 intervention induced weight loss showed significant reduction in the apnea and hypopnea 94 indices (AHI) in conjunction with a decrease in hemoglobin A1c (HbA1c) levels in a randomized 95 controlled trial of obese OSA patients with comorbid diabetes 18 . Further, weight loss following 96 bariatric surgery is effective at improving glycemic control and improving AHI in OSA patients 19 . 97
Intervention studies specifically targeting sleep disruption in OSA patients without any effect on 98 weight, such as continuous positive airway pressure (CPAP) treatment, have shown 99 contradictory results for glycemic control. Most CPAP intervention studies in T2D reported no 100 glycemic benefit from the treatment 20,21 , but one study demonstrated a slight reduction in 101 HbA1c 22 . In contrast, CPAP studies on prediabetic OSA patients showed improvements in 102 insulin sensitivity and glucose tolerance 23, 24 . It is not clear from these studies whether 103 improvement of glycemic control in conjunction with weight loss improves sleep quality or vice-104 versa. 105 A few studies have investigated the impact of dietary macronutrient composition on 106 sleep duration and quality. Two studies reported reduction of slow wave sleep (SWS) and 107 elevation of rapid eye movement (REM) sleep in individuals consuming higher carbohydrates 108 (600g carbohydrate or 80% energy from carbohydrate) 25, 26 . Another study reported the effect of 109 a high carbohydrate (56% energy from carbohydrate) diet in reducing sleep onset latency when 110 compared to a control diet 27 . Studies investigating low carbohydrate diets showed the opposite 111 effect; reduced REM 28 , increased REM onset latency 29 and increased SWS 28 , even after 4 112 hours of administering a very low carbohydrate meal 28 . Collectively, these findings signify 113 dietary carbohydrate content as an important factor in modulating sleep architecture, but 114 extrapolation from these studies is limited since they were conducted in experimentally 115 controlled conditions with small numbers of healthy individuals in a short time-span and with 116 diets administered at specific time points. 117 Population and intervention-based studies on the overall impact of carbohydrate intake 118 on sleep indices or sleep quality are very limited. Katagiri The purpose of this study was to assess the effect of the intervention by time-interval on the 132 global PSQI and its seven component scores as well as compared its changes with different 133 intervention and disease categories. We also assessed the relationship between changes in the 134 sleep parameters versus key biochemical parameters, and also investigated the correlation of 135 pain, circadian rhythm disruption and CPAP usage versus patient-perceived sleep status. We 136 hypothesized that the global sleep indexes would improve analogously, as improvement in other 137 key biochemical parameters observed in the intervention. 138
Materials and Methods 139

Study participants and design 140
This study is part of a clinical trial (Clinical trials.gov identifier: NCT02519309) that was 141 approved by the Franciscan Health Lafayette Institutional Review Board. Patients between age 142 21 and 65 years with either a diagnosis of T2D and a BMI > 25 kg/m 2 or prediabetes and a BMI 143 > 30 kg/m 2 were included in this study. Detailed study design including the inclusion and 144 exclusion criteria were previously reported 34, 35 . Briefly, the trial was an open-label, non-145 randomized, controlled, longitudinal study with patients divided into three groups. The T2D and 146 pre-diabetes patients in the continuous care intervention (CCI) regimen self-selected either on-147 site (CCI-onsite) or web-based (CCI-web) education delivery. Educational content and medical 148 treatment was the same for both CCI-onsite and CCI-web. As there were no significant 149 differences in outcomes including PSQI scores, between educational groups, they are combined 150 for further analysis 34, 35 . Both T2D and prediabetes CCI patients had access to a mobile health 151 application (app) that enabled them to communicate and be continuously monitored by a team 152 of healthcare professionals including a personal health coach and physician or nurse 153 practitioner. Patients received individualized guidance in achieving nutritional ketosis, typically 154 including restriction of daily dietary carbohydrates to less than 30 grams. Patients were 155 encouraged to measure and input weight, blood glucose and blood beta-hydroxybutyrate (BHB) 156 concentrations daily in the app. These measurements were used by the health care team for monitoring the patient's condition (weight and glucose) and assessing carbohydrate restriction 158 (BHB). 159
Separately recruited usual care (UC) T2D patients were participants in a local diabetes 160 education program including care by their primary care physician or endocrinologist and 161 counseling by registered dietitians; no modification to their care was made for the study. This 162 group was observed at baseline and one year as reference for typical disease treatment and 163 progression within the same geography and health system. (UC patients were informed that the 164 trial had an intervention arm and could participate in that group if they chose to do so). 165
Demographic and clinical variables 166
Patient demographic and clinical data were collected at baseline, 70 days and one year. those with bedtimes between 12am to 6pm were bedtime shifted. These arbitrary bedtime and 201 wake time cut-off ranges were selected based on evening and night shift workers schedule (2nd 202 shift -3pm to 11pm and 3rd shift-11pm to 7am); which causes these workers to have sleep 203 patterns that deviate from a normal chronotype. Patients were also surveyed regarding CPAP 204 usage and discontinuation, however detailed usage information such as CPAP pressure 205 settings and usage compliance were not obtained making it difficult to interpret the patients OSA 206 treatment status. 207 208
Statistical Analyses 210
The questionnaires were administered by research personal and completed by patients 211 on paper. Paper questionnaires were scanned and responses were transcribed in duplicate by 212 an independent contract data entry firm. The patterns of missing data were assessed using 213
Little's MCAR test 39 and were found to be missing at random (MAR Adjusted Pearson's and Spearman correlations were calculated between changes from 226 baseline in global PSQI and changes in metabolic-parameters. Adjusted correlations were 227 performed while controlling for age, gender and BMI at baseline. All participants in the CCI 228 group were stratified by sleep improvement status based on their baseline and one year global 229 PSQI scores. Patients that were initially considered "poor sleepers" with a baseline PSQI > 5 230 but whose score after one year decreased to at or below the threshold of 5 were classified as 231 improved. Those patients who were considered "good sleepers" at both baseline and one year 232 were classified as maintained. Finally, those patients whose 1 year PSQI score was >5 233 (regardless of their baseline score) were classified as not improved. Stepwise analyses of 234 covariance (ANCOVA) were performed between the three different CCI sleep status groups at baseline characteristics of the participants that were included for assessments of sleep are 246 presented in Table 1 . One-hundred forty-three (54.6%) CCI T2D, 61(54%) CCI prediabetes, and 247 53 (62.3%) UC T2D patients completed the PSQI at all expected time points. The patients who 248
completed the trial at one year were slightly higher than those who completed the PSQI 249 questionnaires. Some of the patients completed the study period and laboratory analysis but 250 were unable to attend the clinic for their 70-days and one-year follow-up visits, where they are 251 required to complete their corresponding questionnaires. The proportion of missing PSQI data 252 were similar across the three groups with 77.61% of CCI T2D, 79.06% of CCI prediabetes and 253 79.24% of UC T2D completed the PSQI in all expected time points. There were no significant 254 differences between completers and non-completers on baseline characteristics for either group 255
at one year of the intervention (supplemental Table 1 ). The global PSQI and component scores 256 did not differ significantly among the groups (CCI T2D, CCI prediabetes and UC T2D) at 257 baseline. The proportion of participants with overall poor sleep quality was higher in the CCI 258 prediabetes group (77.9%) compared to the CCI T2D (68.3%) and UC T2D (68.2%) groups. 259
Effect of intervention on sleep 260
Global PSQI and component scores 261
Overall sleep quality as assessed by the global PSQI score, improved in CCI T2D 262 (median change from 7 to 6; p<0.001) and prediabetes (median change from 7 to 5; p<0.001) 263 groups after one year of the intervention (Figure 1 ). No significant change in the global PSQI 264 score was observed in UC T2D (median change from 7 to 8, p=0.245). At one year, global PSQI 265 scores in the CCI T2D (p<0.001) and prediabetes (p<0.01) were significantly lower than in the 266 UC T2D, whereas no differences were observed at baseline (Figure 2A ). Among patients 267 characterized as poor sleepers at baseline (global PSQI >5), one year global PSQI score was 268 lower in the CCI T2D (p<0.001) and prediabetes (p<0.001) than in the UC T2D ( Figure 2B ). 269
Greater reduction in the global PSQI score was observed in CCI T2D (median change of -1, 270 p<0.01) and CCI prediabetes groups (median change of -2, p<0.001) compared to the UC T2D 271 group (Figure 3 ). Further assessment of the PSQI component scores revealed three of the 272 seven components showed significant change at one year for CCI T2D and prediabetes groups. 273
Subjective sleep quality (p<0.01 CCI T2D; p<0.001 CCI prediabetes), sleep disturbance (p<0.01 274 CCI T2D; p<0.001 CCI prediabetes) and daytime dysfunction (p<0.001 CCI T2D; p<0.001 CCI 275 prediabetes) score were lower in the CCI T2D and prediabetes patients compared to the UC 276 T2D group at one year (Figure 4 A-C). 277
Resolution of poor sleep quality 278
There were 179 (68.3%) T2D and 88 (77.9%) prediabetes patients categorized as "poor 279 sleepers" in the CCI at baseline. The proportions of "poor sleepers" in the CCI were reduced 280
after one year of the intervention, with 56.5% of T2D (p=0.001) and 48.7% (p<0.001) of 281 prediabetes patients categorized as "poor sleepers" at one year. In the UC cohort, the 282 proportion of patients categorized as "poor sleepers" did not change after one year (68.2% at 283 baseline to 69.4% at one year). 284 Table 2 shows correlations between changes in the global PSQI score with changes in 287 glucose-related, ketone and inflammatory markers in the CCI. In the prediabetes group, 288 changes in fasting glucose (r= 0.23, p=0.02) and HOMA-IR (r= 0.32, p<0.001) were correlated 289 to changes in PSQI scores after controlling for baseline age, sex and weight. Increased ketone 290 concentrations in the prediabetes participants were also associated with reduction of global 291 PSQI scores (r= -0.242, p=0.01). These correlations observed in the prediabetes group were 292 not present in the CCI T2D group and changes in the HbA1c and hsCRP did not correlate with 293 changes in global PSQI scores in either group. Change in mean weight (p=0.04) and HOMA-IR 294 (p=0.01) were the only variables independently and significantly associated between the three 295 different sleep status (improved, maintained and not improved sleep status) at one year of the 296 intervention. No statistically significant differences were found in weight loss changes between 297 patients with improved, maintained and not improved sleep status. Patients who maintained 298 sleep showed highest reductions of HOMA-IR (-6.94 + 0.86), with statistically significant 299 difference than those who did not improve sleep, after one year of the intervention (p = 0.02). 
Association within the CCI group between changes in global PSQI with metabolic and 285 inflammatory markers
Effect of CPAP usage on sleep improvement 324
At baseline, there were a total of 140 participants in both CCI and UC treatment groups 325 with CPAP equipment prescribed for sleep. Among CPAP users, 91 were in the CCI T2D group, 326 31 in the CCI prediabetes and 18 in the UC T2D group. Fifteen (13 CCI T2D and 2 UC T2D) of 327 the 140 participants discontinued using CPAP at one year. Only 6 (46%) of the 13 CCI T2D 328 participants discontinued due to patient-reported improvement in sleep quality from the CCI and 329 reduction of weight; the remaining 7 reported dis-continuation due to discomfort or personal 330 choice. Global PSQI scores among the CPAP users at baseline and one year did not show a 331 significantly different distribution pattern than what was observed in the full cohort of 332 participants. 333
Discussion 334
This study is one of the first designed to assess the effect of carbohydrate restriction and 335 nutritional ketosis on sleep quality in individuals with hyperglycemia and insulin resistance. 336
Improved patient-reported sleep quality as assessed by global PSQI suggests that CCI 337 including nutritional ketosis benefited sleep quality in both patients with T2D and prediabetes. 338
The proportion of patients categorized as "poor sleepers" at one year was significantly reduced 339 in the CCI groups but not in the UC group. Furthermore, these results demonstrate that the 340 sleep quality improvement observed in the whole intervention population was due in part to 17% 341 of baseline "poor sleepers" being reclassified as "good sleepers" at one year. Our results are 342 consistent with previous findings that showed improved overall sleep quality in children 343 consuming ketogenic diets 31, 32 . reported a direct correlation between degree of weight loss and global PSQI score improvement 379 in healthy nonobese adults receiving an energy restricted diet, while Chaput et al 52 reported an 380 improvement in global PSQI score following the initial 5-kg weight loss, but no additional 381 improvement with subsequent weight loss. A study using a ketogenic diet in children alleviated 382 abnormal sleep architecture; however, weight loss was suggested as the main determinant of 383 improved sleep 33 . These studies collectively imply a direct association between weight loss and 384 improved PSQI score. Likewise, long-term maintenance of weight loss was associated with 385 better sleep quality and quantity (); while the degree of weight loss reduction is directly 386 correlated with OSA improvement(). However, some studies also demonstrate the efficacy of 387 anti-glycemic medications for improving PSQI score concurrent with improved glycemic control 388 53 . This study identified associations between HOMA-IR and weight reductions with stratification 389 of patients' sleep status in the full CCI cohort even though there were no significant differences 390 in weight loss and insulin resistance reduction levels between those who had improved sleep 391 and those who did not. Patients with good sleep quality at the beginning of the intervention 392 benefited the most in reducing insulin resistance. Improvement in fasting glucose and HOMA-IR 393 were only positively associated with improved PSQI score in prediabetes patients. 394
It is not clear if nutritional ketosis achieved by substantial carbohydrate restriction 395 augmented the effect of the intervention on sleep or if weight loss and/or improved glycemic 396 control generated from the intervention contributed to sleep quality improvements. We showed 397 a significant correlation between blood beta-hydroxybutryrate (BHB) levels and PSQI 398 improvement in the prediabetes cohort. While the effect of and mechanism of BHB in sleep are 399 not clear, a positive correlation between blood BHB levels and carbon dioxide (CO 2 ) response 400 was previously reported in patients with obesity related hypoventilation syndrome that had 401 reduced CO 2 response 54 . A continuous state of ketosis through carbohydrate restriction and fat 402 intake also induces the postprandial release of a satiety hormone, cholecystokinin (CCK) 28,55,56 . 403
When administered in rats, CCK was shown to promote slow wave activity and NREM sleep 57 . 404 CCK was also shown to induce sleep when administered in diabetic rats 58 . Therefore, it is 405 possible that one mechanism of improved sleep with a ketogenic diet that increases BHB levels 406 is through CCK induction. 407
There are several limitations of our study. The study was designed mainly to assess the 408 impact of the CCI on glycemic control, medication use, weight, and cardiovascular disease risk 409 factors. Patient-reported outcomes for quality of life measures including sleep were included as 410 secondary endpoints. It is difficult to determine the causality among the intervention, 411 improvement in primary outcomes and improvement in sleep from this study. A major limitation 412 of this study is the use of subjective sleep measures as self-reported sleep assessment is 413 subject to limited self-knowledge of sleep behavior and inconsistency in reporting. Therefore, 414 future studies that use randomized controlled trial designs and objective sleep measures are 415 needed to confirm our results. In addition, patients with an established diagnosis of a sleep 416 disorder such as OSA were not separated in the analysis since complete records of their CPAP 417 usage were not collected in the questionnaire. Patient compliance with CPAP usage is essential 418 for making interpretations about the status of their OSA treatment and its effect on sleep and 419 glycemic control. The study also lacked recruitment of prediabetes patients in the UC group for 420 direct comparison of the treatment effect between UC and CCI on sleep in these patients. 421
In conclusion, these results demonstrate that overall sleep quality significantly improved 422 in T2D and prediabetes patients undergoing remote CCI including nutritional ketosis but not in 423 
